BIBvsIBB
ProShares Ultra Nasdaq Biotechnology against iShares Biotechnology ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BIB | IBB | |
|---|---|---|
| Expense ratio | 0.95% | 0.45% |
| Assets | $104M | $10.6B |
| Net flow, 1 month | +$2M | +$59M |
| Net flow, 1 year | −$10M | +$1.6B |
| Return, YTD | +53.4% | +26.4% |
| Return, 1 year | +115.2% | +52.7% |
| Avg daily volume | 11K | 1.6M |
| Holdings | 229 | 221 |
| Listed | Apr 8, 2010 | Feb 4, 2001 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS